AHR and breast cancer: Such cross-talk through altered p300 recruitment to Nrf2-regulated target genes was shown in ER(+) MCF7 breast cancer cells treated with racemic SFN, a combination of AhR and ERα activator, and 17β-estradiol (E2) [12].